ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Benefits of Prophylactic Emicizumab in Enhancing Immune Tolerance Induction in a Hemophiliac Boy with Very High Inhibitor Titer

N. Sirachainan1, A. Chuansumrit1, S. Parapakpenjune2, P. Wongwerawattanakoon3, S. Lertthammakiat4, P. Kadegasem1, W. Sasanakul1

1Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 2Department of Pediatrics, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand, 3Department of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4Department of Pediatrics, Chakri Naruebodindra Medical Institute, Samut Prakan, Thailand

Abstract Number: PB0630

Meeting: ISTH 2021 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Approximately 20-30% of severe hemophilia A patients develop inhibitor, causing more frequent bleeding episodes.  Immune tolerance induction (ITI) therapy is a mandatory treatment option. During ITI, patients have bleeding risk, as a result, prophylaxis with bypassing agents has been reported. Emicizumab, a bispecific antibody to factor IXa and factor X, has been used as prophylactic treatment among hemophilia A patient with inhibitor.

Aims: To report the benefit of prophylactic emicizumab in enhancing ITI in a boy with severe hemophilia A and high inhibitor titer.

Methods: A descriptive report.

Results: Case report: A 2-year-old boy with severe hemophilia A developed inhibitor of 16.9 Bethesda units (BU) after receiving factor VIII concentrates to treat 2 subdural hemorrhages.  At 10 years of age, he exhibited extensive intracerebral bleeding inducing obstructive hydrocephalus requiring bilateral ventriculostomy. He required aPCC 82,500 units, rFVIIa 140 mg, and plasma exchange with high dose factor VIII concentrates (54,530 units) to control bleeding resulting in being bedridden. The ITI was initiated at the inhibitor of 140 BU and historic peak inhibitor of 3,360 BU with EHL factor VIII 100 units /kg 3 times weekly. The peak inhibitor during ITI was 380 BU with one of each episode of intramuscular and joint bleeding. The inhibitor titer was 17.2 BU at the end of the first year of ITI. Then, 3 mg/kg weekly for 4 doses and 6 mg/kg every 4 weeks of emicizumab prophylaxis was added in the second year of ITI. The inhibitor further declined to  0.6 BU at the end of third year of ITI. He finally achieved a partially successful ITI at the end of 3.5 years of ITI. His factor VIII:C recovery was 60% and half-life at 5.5 hours.

Conclusions: Additional emicizumab resulting in zero bleeding was helpful in enhancing ITI in a hemophilia boy with very high inhibitor titer.

To cite this abstract in AMA style:

Sirachainan N, Chuansumrit A, Parapakpenjune S, Wongwerawattanakoon P, Lertthammakiat S, Kadegasem P, Sasanakul W. Benefits of Prophylactic Emicizumab in Enhancing Immune Tolerance Induction in a Hemophiliac Boy with Very High Inhibitor Titer [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/benefits-of-prophylactic-emicizumab-in-enhancing-immune-tolerance-induction-in-a-hemophiliac-boy-with-very-high-inhibitor-titer/. Accessed October 2, 2023.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/benefits-of-prophylactic-emicizumab-in-enhancing-immune-tolerance-induction-in-a-hemophiliac-boy-with-very-high-inhibitor-titer/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley